pentamidine has been researched along with Co-infection in 6 studies
Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.
pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Chechi, F | 1 |
| Corsi, P | 1 |
| Bartolozzi, D | 1 |
| Gaiera, G | 1 |
| Bartoloni, A | 1 |
| Zammarchi, L | 1 |
| Diro, E | 3 |
| Ritmeijer, K | 3 |
| Boelaert, M | 1 |
| Alves, F | 2 |
| Mohammed, R | 2 |
| Abongomera, C | 2 |
| Ravinetto, R | 1 |
| De Crop, M | 1 |
| Fikre, H | 3 |
| Adera, C | 1 |
| van Loen, H | 1 |
| Tsoumanis, A | 1 |
| Adriaensen, W | 2 |
| Hailu, A | 2 |
| Griensven, JV | 1 |
| Vogt, F | 1 |
| Mengesha, B | 1 |
| Asmamaw, H | 1 |
| Mekonnen, T | 1 |
| Takele, Y | 1 |
| Adem, E | 1 |
| Melsew, Y | 1 |
| van Griensven, J | 2 |
| Edwards, T | 1 |
| Kibret, A | 1 |
| Bardonneau, C | 1 |
| Soipei, P | 1 |
| Mutinda, B | 1 |
| Omollo, R | 1 |
| Zijlstra, EE | 1 |
| Wasunna, M | 1 |
| Alvar, J | 1 |
| Alexander, N | 1 |
| Blesson, S | 1 |
| Boodman, C | 1 |
| Libman, M | 1 |
| Ndao, M | 1 |
| Yansouni, CP | 1 |
| Faucher, JF | 1 |
| Morquin, D | 1 |
| Reynes, J | 1 |
| Chirouze, C | 1 |
| Hoen, B | 1 |
| Le Moing, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Secondary Prophylaxis of Visceral Leishmaniasis Relapses in HIV Co-infected Patients Using Pentamidine as a Prophylactic Agent: a Prospective Cohort Study[NCT01360762] | Phase 3 | 74 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| A Randomized Trial of Ambisome Monotherapy and Combination of Ambisome and Miltefosine for the Treatment of VL in HIV Positive Patients in Ethiopia Followed by Secondary VL Prophylactic Treatment With Pentamidine.[NCT02011958] | Phase 3 | 59 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of patients with SAEs which are possibly, probably or definitely drug-related following clinician's assessment or that lead to permanent drug discontinuations during the first year of pentamidine administration (NCT01360762)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Pentamidine Secondary Prophylaxis (PSP) | 3 |
During the first year of pentamidine administration for prophylaxis: participants with any drug-related non-serious adverse events (with drug-related defined as possibly, probably or definitely related to primary therapy following physicians assessment) as well as any serious adverse events (drug-related or not) (NCT01360762)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Drug-related non-serious adverse events | Any serious adverse event | |
| Pentamidine Secondary Prophylaxis (PSP) | 30 | 17 |
The number of required additional clinical interventions/therapeutic procedures (NCT01360762)
Timeframe: 30 months
| Intervention | number of events (Number) | |||
|---|---|---|---|---|
| Additional IV fluid during PM administration | Prolonged hospital observation | additional medication during PM infusion | Additional IV or oral glucose | |
| Pentamidine Secondary Prophylaxis (PSP) | 10 | 2 | 2 | 1 |
Number of treatment discontinuations and interruptions/missed doses. (NCT01360762)
Timeframe: 30 months
| Intervention | number of events (Number) | ||
|---|---|---|---|
| Permanent discontinuation | Missed more than 1 dose | Treatment interruption | |
| Pentamidine Secondary Prophylaxis (PSP) | 2 | 4 | 0 |
Probability of relapse-free survival up to one year after the start of the intervention (PSP) (at month 6 and month 12) (NCT01360762)
Timeframe: up to 1 year after the start of the intervention (PSP)
| Intervention | percentage probability (Number) | |
|---|---|---|
| Probability of relapse-free survival at 6 months | Probability of relapse-free survival at 12 months | |
| Pentamidine Secondary Prophylaxis (PSP) | 79 | 71 |
2 trials available for pentamidine and Co-infection
| Article | Year |
|---|---|
Long-term Clinical Outcomes in Visceral Leishmaniasis/Human Immunodeficiency Virus-Coinfected Patients During and After Pentamidine Secondary Prophylaxis in Ethiopia: A Single-Arm Clinical Trial.
Topics: Adult; Antiprotozoal Agents; Coinfection; Ethiopia; Female; HIV Infections; Humans; Leishmaniasis, V | 2018 |
Antigen Detection in Urine for Noninvasive Diagnosis and Treatment Monitoring of Visceral Leishmaniasis in Human Immunodeficiency Virus Coinfected Patients: An Exploratory Analysis from Ethiopia.
Topics: Adult; Antigens, Protozoan; Antiprotozoal Agents; Antiretroviral Therapy, Highly Active; CD4 Lymphoc | 2018 |
4 other studies available for pentamidine and Co-infection
| Article | Year |
|---|---|
Case Report: Intravenous Pentamidine Rescue Treatment for Active Chronic Visceral Leishmaniasis in an HIV-1 Infected Patient.
Topics: Administration, Intravenous; AIDS-Related Opportunistic Infections; Antiprotozoal Agents; Coinfectio | 2021 |
Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia.
Topics: Adult; Antiprotozoal Agents; CD4 Lymphocyte Count; Cohort Studies; Coinfection; Ethiopia; Female; HI | 2019 |
Case Report:
Topics: Coinfection; Congo; Female; Fever; HIV Infections; HIV-1; Humans; Middle Aged; Multiple Myeloma; Pen | 2019 |
Serial use of pentamidine and miltefosine for treating Leishmania infantum-HIV coinfection.
Topics: Antiprotozoal Agents; Coinfection; HIV Infections; Humans; Immunocompromised Host; Leishmania infant | 2016 |